| 臺大學術典藏 |
2021-10-14T02:45:28Z |
Erratum: Correction: Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy (eLife (2018) 7 PII: e43237)
|
Springer S.U.; Chen C.-H.; Rodriguez Pena M.D.C.; Li L.; Douville C.; Wang Y.; Cohen J.D.; Taheri D.; Silliman N.; Schaefer J.; Ptak J.; Dobbyn L.; Papoli M.; Kinde I.; Afsari B.; Tregnago A.C.; Bezerra S.M.; VandenBussche C.; Fujita K.; Ertoy D.; Cunha I.W.; Yu L.; Bivalacqua T.J.; Grollman A.P.; Diaz L.A.; Karchin R.; Danilova L.; CHAO-YUAN HUANG; Shun C.-T.; Turesky R.J.; Yun B.H.; Rosenquist T.A.; Pu Y.-S.; Hruban R.H.; Tomasetti C.; Papadopoulos N.; Kinzler K.W.; Vogelstein B.; Dickman K.G.; Netto G.J. |
| 臺大學術典藏 |
2021-10-14T02:45:27Z |
The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center
|
Cheng Y.-T.; Chiang C.-H.; Pu Y.-S.; Liu S.P.; Lu Y.-C.; Chang Y.-K.; Chang H.-C.; Huang K.-H.; Lee Y.-J.; Chow P.-M.; Hung S.-C.; CHAO-YUAN HUANG |
| 臺大學術典藏 |
2021-10-14T02:45:26Z |
Nuclear factor-κB overexpression is correlated with poor outcomes after multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer
|
Chiang Y.; Wang C.-C.; Tsai Y.-C.; CHAO-YUAN HUANG; Pu Y.-S.; Lin C.-C.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-10-14T02:45:26Z |
Trifecta outcome of ureteral reconstruction in iatrogenic injury and non-iatrogenic ureteral lesions: a 10-year experience at a tertiary referral center
|
Tseng C.-S.; Tai T.-E.; Hong C.-H.; Chen C.-H.; Chiang I.-N.; Lu Y.-C.; Hung S.-C.; Huang K.-H.; CHAO-YUAN HUANG; Chang H.-C.; Pu Y.-S.; Chow P.-M. |
| 臺大學術典藏 |
2021-10-14T02:45:25Z |
The impact of primary location and age at orchiopexy on testicular atrophy for congenital undescended testis
|
Tseng C.-S.; Huang K.-H.; Kuo M.-C.; Hong C.-H.; Chen C.-H.; Lu Y.-C.; CHAO-YUAN HUANG; Pu Y.-S.; Chang H.-C.; Chiang I.-N. |
| 臺大學術典藏 |
2021-10-14T02:45:23Z |
Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study
|
Huang W.-L.; Huang K.-H.; CHAO-YUAN HUANG; Pu Y.-S.; Chang H.-C.; Chow P.-M. |
| 臺大學術典藏 |
2021-10-14T02:45:22Z |
Polymorphism of nucleotide binding domain-like receptor protein 3 (NLRP3) increases susceptibility of total urinary arsenic to renal cell carcinoma
|
Chung C.-J.; Bao B.-Y.; Lin Y.-C.; Huang Y.-L.; Shiue H.-S.; Ao P.-L.; Pu Y.-S.; CHAO-YUAN HUANG; Hsueh Y.-M. |
| 臺大學術典藏 |
2021-10-14T02:45:22Z |
Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy
|
Cheng Y.-T.; CHAO-YUAN HUANG; Chen C.-H.; Chiu S.-T.; Hong J.-H.; Pu Y.-S.; Liu S.-P.; Lu Y.-C.; Chang Y.-K.; Chang H.-C.; Huang K.-H.; Lee Y.-J.; Chow P.-M.; Chiang I.-N.; Hung S.-C.; Chiang C.-H. |
| 臺大學術典藏 |
2021-10-14T02:45:21Z |
Effect of plasma selenium, red blood cell cadmium, total urinary arsenic levels, and eGFR on renal cell carcinoma
|
Hsueh Y.-M.; Lin Y.-C.; Huang Y.-L.; Shiue H.-S.; Pu Y.-S.; CHAO-YUAN HUANG; Chung C.-J. |
| 臺大學術典藏 |
2021-10-14T02:45:20Z |
Additive effects of arsenic and aristolochic acid in chemical carcinogenesis of upper urinary tract urothelium
|
Chen C.-H.; Grollman A.P.; CHAO-YUAN HUANG; Shun C.-T.; Sidorenko V.S.; Hashimoto K.; Moriya M.; Turesky R.J.; Yun B.H.; Tsai K.; Wu S.; Chuang P.-Y.; Tang C.-H.; Yang W.-H.; Tzai T.-S.; Tsai Y.-S.; Dickman K.G.; Pu Y.-S. |
| 臺大學術典藏 |
2021-10-14T02:45:20Z |
Outcomes of stratified transurethral resection of bladder tumor: A propensity score-matched analysis
|
Huang W.-L.; CHAO-YUAN HUANG; Huang K.-H.; Pu Y.-S.; Chang H.-C.; Chow P.-M. |
| 臺大學術典藏 |
2021-10-14T02:45:18Z |
Outcomes and prediction models for exclusive prostate bed salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy
|
Tseng C.-S.; Wang Y.-J.; Chen C.-H.; Wang S.-M.; Huang K.-H.; Chow P.-M.; Pu Y.-S.; CHAO-YUAN HUANG; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-09-04T06:24:13Z |
Antiandrogen hepatotoxicity in patients with chronic viral hepatitis
|
Pu Y.-S.; Liu C.-M.; JIA-HORNG KAO; Chen J.; Lai M.-K. |
| 臺大學術典藏 |
2021-09-01T02:02:46Z |
Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study
|
ANN-LII CHENG; Su I.-J.; Chen C.-C.; Tien H.-F.; Lay J.-D.; Chen B.-R.; Pu Y.-S.; Hong R.-L.; Shen M.-C.; Wang C.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:44Z |
Tamoxifen Enhances the Chemosensitivity of Bladder Carcinoma Cells
|
Pu Y.-S.; Hsieh T.-S.; Tsai T.-C.; ANN-LII CHENG; Hsieh C.-Y.; Su I.-J.; Lai M.-K. |
| 臺大學術典藏 |
2021-09-01T02:02:43Z |
Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: A potential use in intravesical chemotherapy
|
Pu Y.-S.; Hsieh T.-S.; ANN-LII CHENG; Tseng N.-F.; Su I.-J.; Hsieh C.-Y.; Lai M.-K.; Tsai T.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:43Z |
Expression of mdr-1 gene in transitional cell carcinoma and its correlation with chemotherapy response
|
Pu Y.-S.; Tsai T.-C.; ANN-LII CHENG; Tsai C.-Y.; Tseng N.-F.; Su I.H.-J.; Hsieh C.-Y.; Lai M.-K. |
| 臺大學術典藏 |
2021-09-01T02:02:35Z |
Megestrol acetate antagonizes cisplatin cytotoxicity
|
Pu Y.-S.; ANN-LII CHENG; Chen J.; Guan J.-Y.; Lu S.-H.; Lai M.-K.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
|
Hsu C.-H.; Chen J.; Wu C.-Y.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.; Hsu C.-H.; Chen J.; Tsai T.-C.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:20Z |
Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells
|
Pu Y.-S.; Hour T.-C.; Chuang S.-E.; ANN-LII CHENG; Lai M.-K.; Kuo M.-L. |
| 臺大學術典藏 |
2021-09-01T02:02:11Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Chen J.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:09Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:06Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
